<DOC>
	<DOCNO>NCT00483743</DOCNO>
	<brief_summary>This study ass compare safety tolerability inhale TPI 1020 ( repeat nominal dos ; 500 μg BID x 6 week ) versus inhale budesonide ( repeated dos ; 800 μg BID x 6 week ) match placebo . Pharmacodynamic ( PD ) activity FEV1 , sputum blood cell cytokine also study .</brief_summary>
	<brief_title>Safety , Tolerability PD Activity Inhaled TPI 1020 Versus Inhaled Budesonide COPD Patients</brief_title>
	<detailed_description>A multi-centre , randomize , placebo active-controlled , 6-week study inhale TPI 1020 , inhale budesonide match placebo ( random allocation eligible patient three treatment ratio 3:3:1 ) , evaluate safety , tolerability pharmacodynamic activity TPI 1020 42 evaluable COPD subject .</detailed_description>
	<mesh_term>Bronchitis</mesh_term>
	<mesh_term>Budesonide</mesh_term>
	<criteria>Outpatients , male female , smoker exsmoker ( quit least year ago ) smoke history equal great 10 pack year . Age 40 80 year old diagnosis ( least 12 month ) mild moderate COPD COPD exacerbation indicate treatment oral systemic glucocorticosteroids and/or hospitalization and/or clinically relevant respiratory infection require antibiotic within 3 month start study . Failure produce sufficient sputum sample screen sputum induction procedure , require TCC differential cell count determination .</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2012</verification_date>
</DOC>